非小细胞肺癌表皮生长因子受体酪氨酸激酶抑制剂耐药机制(5)
[19] Smolen， G.A.， et al.， Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A， 2006. 103(7)： p. 2316-21.[20] Bean， J.， et al.， MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A ......
您现在查看是摘要页，全文长 3253 字符。